Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gore's updated septal occluder:

This article was originally published in Clinica

Executive Summary

WL Gore and Associates' next-generation version of its Gore Helex septal occluder has been granted premarket approval (PMA) by the US FDA. The implantable device, used to close up atrial septal defects (ASDs), has a modified catheter delivery system, which enables easier device deployment via standard femoral venous access, claimed the Flagstaff, Arizona firm. The Gore Helex is made of the biocompatible material ePTFE, which encourages tissue ingrowth, and is supported by a nitinol wire frame. Cells grow across the device to eventually occlude the ASD, to prevent shunting of blood between the two atria. The original Gore Helex device was approved in August 2006. The device is most often used to treat children with ASD.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049982

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel